Timothy J.  Richmond net worth and biography

Timothy Richmond Biography and Net Worth

EVP of AbbVie
Tim Richmond is Executive Vice President, Chief Human Resources Officer for AbbVie, responsible for leading a global human resources organization focused on engaging high-performing employees and amplifying a culture that drives business performance. As a result of this focus, AbbVie has been named to more than 40 Great Place to Work® and Top Employer® lists and is prominently recognized on “Best of” lists related to diversity, leadership and engagement, as well as for corporate responsibility and business performance.

Prior to AbbVie, Mr. Richmond served as Divisional Vice President, Compensation and Benefits at Abbott. He also held various human resources management positions at 3M Company.

Tim serves on the Board of the Human Resources Policy Association, on the Advisory Board for the Center on Executive Compensation, and as Chairman of the Advisory Board for the University of South Carolina’s Center for Executive Succession. Mr. Richmond also serves on the Board of Directors for the Warriors & Quiet Waters Foundation and the Travis Manion Foundation, both focused on supporting veterans and strengthening communities. In 2020, Tim was named a Fellow of the National Academy of Human Resources.  

Mr. Richmond earned a bachelor’s degree in journalism and mass communications from the University of Minnesota and a master’s degree in labor and industrial relations from Michigan State University.

What is Timothy J. Richmond's net worth?

The estimated net worth of Timothy J. Richmond is at least $2.43 million as of December 12th, 2022. Mr. Richmond owns 13,837 shares of AbbVie stock worth more than $2,429,500 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Richmond may own. Additionally, Mr. Richmond receives a salary of $1,120,000.00 as EVP at AbbVie. Learn More about Timothy J. Richmond's net worth.

How old is Timothy J. Richmond?

Mr. Richmond is currently 58 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Timothy J. Richmond's age.

What is Timothy J. Richmond's salary?

As the EVP of AbbVie Inc., Mr. Richmond earns $1,120,000.00 per year. There are 5 executives that earn more than Mr. Richmond. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,190,000.00 per year. Learn More on Timothy J. Richmond's salary.

How do I contact Timothy J. Richmond?

The corporate mailing address for Mr. Richmond and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Timothy J. Richmond's contact information.

Has Timothy J. Richmond been buying or selling shares of AbbVie?

Timothy J. Richmond has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Timothy J. Richmond sold 42,370 shares of the business's stock in a transaction on Monday, December 12th. The shares were sold at an average price of $163.44, for a transaction totalling $6,924,952.80. Following the completion of the sale, the executive vice president now directly owns 13,837 shares of the company's stock, valued at $2,261,519.28. Learn More on Timothy J. Richmond's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 13 times. They sold a total of 737,381 shares worth more than $130,442,034.24. The most recent insider tranaction occured on December, 16th when SVP Kevin K Buckbee sold 1,800 shares worth more than $310,032.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 12/16/2024.

Timothy J. Richmond Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2022Sell42,370$163.44$6,924,952.8013,837View SEC Filing Icon  
12/6/2021Sell50,350$120.00$6,042,000.00View SEC Filing Icon  
3/1/2021Sell19,514$108.59$2,119,025.2619,514View SEC Filing Icon  
11/27/2020Sell51,990$105.00$5,458,950.0051,990View SEC Filing Icon  
5/5/2020Sell19,445$85.00$1,652,825.00View SEC Filing Icon  
9/27/2019Sell15,515$75.02$1,163,935.30View SEC Filing Icon  
6/15/2018Sell17,588$99.47$1,749,478.36View SEC Filing Icon  
2/28/2018Sell18,129$118.67$2,151,368.4335,717View SEC Filing Icon  
12/18/2017Sell87,040$98.45$8,569,088.00113,118View SEC Filing Icon  
3/10/2017Sell22,451$65.29$1,465,825.7926,078View SEC Filing Icon  
5/10/2016Sell21,583$63.52$1,370,952.1644,615View SEC Filing Icon  
3/1/2016Sell12,866$55.05$708,273.3079,064View SEC Filing Icon  
3/2/2015Sell14,388$60.33$868,028.04View SEC Filing Icon  
See Full Table

Timothy J. Richmond Buying and Selling Activity at AbbVie

This chart shows Timothy J Richmond's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $175.58
Low: $170.66
High: $176.80

50 Day Range

MA: $182.56
Low: $164.91
High: $203.87

2 Week Range

Now: $175.58
Low: $151.29
High: $207.32

Volume

17,695,750 shs

Average Volume

5,604,020 shs

Market Capitalization

$310.27 billion

P/E Ratio

60.97

Dividend Yield

3.54%

Beta

0.58